Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
SARS-CoV-2 variants of concern (VOC) are more transmissible and may have the potential
for increased disease severity and decreased vaccine effectiveness. We estimated the …
for increased disease severity and decreased vaccine effectiveness. We estimated the …
Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes
Importance The incidence of SARS-CoV-2 infection, including among individuals who have
received 2 doses of COVID-19 vaccine, increased substantially following the emergence of …
received 2 doses of COVID-19 vaccine, increased substantially following the emergence of …
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test …
…, S Nasreen, ME Sundaram, SA Buchan, SE Wilson… - bmj, 2021 - bmj.com
Objective To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic
infection and severe outcomes (hospital admission or death). Design Test negative design …
infection and severe outcomes (hospital admission or death). Design Test negative design …
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in …
…, D Lu, TM Harris, K Yu, SE Wilson - JAMA network …, 2022 - jamanetwork.com
Importance Increased rates of myocarditis or pericarditis following receipt of COVID-19
mRNA vaccines have been observed. However, few available data are associated with …
mRNA vaccines have been observed. However, few available data are associated with …
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
…, SA Kitchen, L Nguyen, SA Buchan, SE Wilson… - Bmj, 2022 - bmj.com
Objectives To estimate the marginal effectiveness of a fourth versus third dose and the
vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any …
vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any …
Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes
Importance There is limited comparative epidemiological evidence on outcomes associated
with COVID-19 vaccination during pregnancy; monitoring pregnancy outcomes in large …
with COVID-19 vaccination during pregnancy; monitoring pregnancy outcomes in large …
Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly
A Hinek, SE Wilson - The American journal of pathology, 2000 - Elsevier
Hurler disease resulting from a deficiency in α-l-iduronidase, which causes an accumulation
of dermatan sulfate and heparan sulfate glycosaminoglycans, is characterized by …
of dermatan sulfate and heparan sulfate glycosaminoglycans, is characterized by …
Empathy levels in first-and third-year students in health and non-health disciplines
SE Wilson, J Prescott, G Becket - American journal of pharmaceutical …, 2012 - Elsevier
Objective To compare empathy scores between health professions students (pharmacy and
nursing) and non-health professions (law) students and between first- and third-year …
nursing) and non-health professions (law) students and between first- and third-year …
The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases
SE Wilson, SL Deeks, TF Hatchette, NS Crowcroft - Cmaj, 2012 - Can Med Assoc
Serological surveillance (serosurveillance) provides estimates of population-level immunity
against vaccine-preventable diseases using cross-sectional studies of antibody prevalence. …
against vaccine-preventable diseases using cross-sectional studies of antibody prevalence. …
The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017
S Wijayasri, K Hillier, GH Lim, TM Harris, SE Wilson… - PLoS …, 2019 - journals.plos.org
Background Ontario, Canada introduced a publicly-funded 13-valent pneumococcal conjugate
vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) and …
vaccine (PCV13) for infants in 2010, replacing the 10-valent (PCV10, 2009–2010) and …